SCHEMBL25369304

SCHEMBL25369304

CS(=O)(=O)Nc1cccc(NC(=O)c2cc(C(=O)Nc3ccc(-c4ccncc4)cc3)cs2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHX9 Q08211 1/20 0.52
▸ HPGD P15428 1/20 0.48
▸ NAMPT P43490 1/20 0.47
▸ ROCK1 Q13464 2/20 0.46
▸ PIP4K2A P48426 3/20 0.46
▸ PIP4K2B P78356 3/20 0.46
▸ ROCK2 O75116 2/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP3A5 P20815 1/20 0.46
▸ KCNK3 O14649 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ KCNK9 Q9NPC2 1/20 0.44
▸ USP7 Q93009 1/20 0.44
▸ USP47 Q96K76 1/20 0.44
▸ AURKA O14965 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30544037 1.00 DHX9 (0.52) DHX9HPGDNAMPTROCK1PIP4K2A
SCHEMBL25368259 0.88 ROCK1 (0.50) DHX9HPGDNAMPTROCK1PIP4K2A
SCHEMBL30543946 0.88 DHX9 (0.53) DHX9HPGDKCNK3HTTKDM4E
SCHEMBL25368280 0.88 DHX9 (0.53) DHX9HPGDKCNK3HTTKDM4E
SCHEMBL25368447 0.86 HPGD (0.51) DHX9HPGDKCNK3HTTKDM4E
SCHEMBL25369907 0.85 HPGD (0.56) DHX9HPGDNAMPTKCNK3KDM4E
SCHEMBL30544073 0.85 NAMPT (0.53) DHX9NAMPTPIP4K2APIP4K2BKCNK3
SCHEMBL25366609 0.85 NAMPT (0.53) DHX9NAMPTPIP4K2APIP4K2BKCNK3
SCHEMBL25368034 0.84 KMT2A (0.60) DHX9HPGDKCNK3KCNK9SMN1; SMN2
SCHEMBL25368657 0.83 HPGD (0.51) DHX9HPGDNAMPTKCNK3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US claimed
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed
WO-2023158795-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179013-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF DHX9, DHX29, DDX39B DHX9 1/4885HPGD 852/4885NAMPT 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback